Sumitomo Dainippon Pharma Co. Ltd

Healthcare US DNPUF

9.41USD
0.00(0%)

Last update at 2026-06-18T20:00:00Z

Day Range

10.5010.50

LowHigh

52 Week Range

5.8019.20

LowHigh

Fundamentals

Previous Close 9.41
Market Cap7101.77M
Volume118
P/E Ratio6.02
Dividend Yield-%
EBITDA130002.00M
Revenue TTM453394.99M
Revenue Per Share TTM1141.22
Gross Profit TTM 268585.99M
Diluted EPS TTM2.46

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Income before tax	17611.00M	-323114.00000M	-47920.00000M	82961.00M	77851.00M
Minority interest	-1.00000M	-40.00000M	22202.00M	15813.00M	67608.00M
Net income	23634.00M	-314969.00000M	-74512.00000M	56413.00M	56219.00M
Selling general administrative	135386.00M	429538.00M	373316.00M	249081.00M	190373.00M
Selling and marketing expenses	25000.00M	383621.00M	-	-	-
Gross profit	245395.00M	187981.00M	376625.00M	402908.00M	378179.00M
Reconciled depreciation	25562.00M	37765.00M	41263.00M	38348.00M	22673.00M
Ebit	13023.00M	-355136.00000M	-44761.00000M	86011.00M	80437.00M
Ebitda	38585.00M	-317371.00000M	-3498.00000M	124359.00M	103110.00M
Depreciation and amortization	25562.00M	37765.00M	41263.00M	38348.00M	22673.00M
Non operating income net other	-	-	-	-	-
Operating income	14925.00M	-354859.00000M	-76979.00000M	60234.00M	71224.00M
Other operating expenses	383907.00M	669417.00M	632523.00M	499801.00M	444728.00M
Interest expense	13500.00M	4277.00M	3159.00M	3050.00M	2586.00M
Tax provision	-6024.00000M	-8185.00000M	48794.00M	42361.00M	41022.00M
Interest income	2307.00M	36022.00M	32218.00M	25777.00M	9213.00M
Net interest income	-11193.00000M	31745.00M	29059.00M	22727.00M	6627.00M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-6024.00000M	-8185.00000M	48794.00M	42361.00M	41022.00M
Total revenue	398832.00M	314558.00M	555544.00M	560035.00M	515952.00M
Total operating expenses	230470.00M	542840.00M	453604.00M	342674.00M	306955.00M
Cost of revenue	153437.00M	126577.00M	178919.00M	157127.00M	137773.00M
Total other income expense net	2686.00M	31745.00M	29059.00M	22727.00M	6627.00M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	23635.00M	-314929.00000M	-96714.00000M	40600.00M	36829.00M
Net income applicable to common shares	-	-	-	56413.00M	56219.00M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Total assets	742604.00M	907506.00M	1134742.00M	1308007.00M	1308127.00M
Intangible assets	172509.00M	195652.00M	329314.00M	398692.00M	383406.00M
Earning assets	-	-	-	-	-
Other current assets	44150.00M	37064.00M	17675.00M	10420.00M	8342.00M
Total liab	573125.00M	751370.00M	727960.00M	634438.00M	659949.00M
Total stockholder equity	169479.00M	156063.00M	406749.00M	607888.00M	580570.00M
Deferred long term liab	-	-	-	-	-
Other current liab	154042.00M	155760.00M	229965.00M	207105.00M	203549.00M
Common stock	22400.00M	22400.00M	22400.00M	22400.00M	22400.00M
Capital stock	22400.00M	22400.00M	22400.00M	22400.00M	22400.00M
Retained earnings	46784.00M	-22665.00000M	280999.00M	514210.00M	508677.00M
Other liab	-	-	-	102069.00M	106982.00M
Good will	197406.00M	199783.00M	209415.00M	195144.00M	176492.00M
Other assets	-	-	-	22650.00M	20191.00M
Cash	23116.00M	29047.00M	143478.00M	202984.00M	193698.00M
Cash and equivalents	-	-	-	-	-
Total current liabilities	240603.00M	515474.00M	372694.00M	278373.00M	278147.00M
Current deferred revenue	-	1348.00M	151952.00M	140034.00M	147703.00M
Net debt	282306.00M	398817.00M	191238.00M	66064.00M	80121.00M
Short term debt	46440.00M	289298.00M	90588.00M	25085.00M	9960.00M
Short long term debt	46440.00M	285517.00M	90588.00M	25085.00M	9960.00M
Short long term debt total	305422.00M	427864.00M	334716.00M	269048.00M	273819.00M
Other stockholder equity	-682.00000M	-682.00000M	103350.00M	71278.00M	49493.00M
Property plant equipment	-	-	-	64091.00M	64966.00M
Total current assets	253168.00M	269569.00M	381860.00M	499521.00M	459795.00M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	14052.00M	20672.00M
Short term investments	16840.00M	7085.00M	20174.00M	35596.00M	29480.00M
Net receivables	74840.00M	81023.00M	106128.00M	151500.00M	136060.00M
Long term debt	258982.00M	133367.00M	244128.00M	243963.00M	263859.00M
Inventory	94222.00M	115350.00M	94405.00M	99021.00M	92215.00M
Accounts payable	38544.00M	67720.00M	52141.00M	46183.00M	64638.00M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	100977.00M	157010.00M	-	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	66751.00M	2239.00M	30566.00M	47661.00M	39722.00M
Deferred long term asset charges	-	-	-	-	-
Non current assets total	489436.00M	637937.00M	752882.00M	808486.00M	848332.00M
Capital lease obligations	-	-	-	-	-
Long term debt total	-	-	-	-	-

Breakdown	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2025-03-31	2024-03-31	2023-03-31	2022-03-31	2021-03-31
Investments	106846.00M	33036.00M	52419.00M	-6433.00000M	-1225.00000M
Change to liabilities	-	-	-	-28669.00000M	50747.00M
Total cashflows from investing activities	99754.00M	33036.00M	-	-18278.00000M	8875.00M
Net borrowings	-112485.00000M	84000.00M	-	-4931.00000M	-24033.00000M
Total cash from financing activities	-108836.00000M	77851.00M	-146817.00000M	-21426.00000M	-57215.00000M
Change to operating activities	-	-	-	22803.00M	102102.00M
Net income	23635.00M	-314929.00000M	-96714.00000M	40600.00M	36829.00M
Change in cash	-5931.00000M	-114431.00000M	-59506.00000M	9286.00M	91990.00M
Begin period cash flow	29047.00M	143478.00M	202984.00M	193698.00M	101708.00M
End period cash flow	23116.00M	29047.00M	143478.00M	202984.00M	193698.00M
Total cash from operating activities	16500.00M	-241893.00000M	11937.00M	31239.00M	135601.00M
Issuance of capital stock	-	-	-	-	-
Depreciation	25562.00M	37765.00M	41263.00M	38348.00M	22673.00M
Other cashflows from investing activities	-52.00000M	10000.00M	-	-797.00000M	225.00M
Dividends paid	3.00M	2792.00M	-11125.00000M	-11126.00000M	-11120.00000M
Change to inventory	18837.00M	-11795.00000M	4560.00M	5356.00M	-10039.00000M
Change to account receivables	-909.00000M	23390.00M	-	-6097.00000M	185.00M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	3652.00M	-3357.00000M	-115632.00000M	-5340.00000M	-43135.00000M
Change to netincome	-	-	-	-41102.00000M	-15829.00000M
Capital expenditures	13030.00M	15730.00M	12742.00M	13494.00M	10806.00M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	-18770.00000M	-108115.00000M	34878.00M	-33733.00000M	66327.00M
Stock based compensation	-	-	-	-	-
Other non cash items	-13927.00000M	143386.00M	32510.00M	-13976.00000M	9772.00M
Free cash flow	3470.00M	-257623.00000M	-805.00000M	17745.00M	124795.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (USD)	Price (USD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
DNPUF Sumitomo Dainippon Pharma Co. Ltd	- -%	9.41	6.02	15.22	0.02	3.16	2.28	6.43
ZTS Zoetis Inc	-2.82 3.58%	75.89	40.18	30.96	10.67	17.60	11.27	26.18
MKKGY Merck KGaA ADR	-0.19 0.62%	30.56	21.25	14.93	3.10	2.14	3.60	12.98
MKGAF MERCK Kommanditgesellschaft auf Aktien	- -%	157.12	21.73	14.95	3.16	2.15	3.56	12.82
GALDY GALDERMA GROUP AG	- -%	42.94	74.21	41.67	8.64	5.55	9.15	42.22

Reports Covered

View All

Profile

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Sumitomo Dainippon Pharma Co. Ltd

6-8, Doshomachi 2-chome, Osaka, Japan, 541-0045

81 6 6203 5321
https://www.sumitomo-pharma.com
Employees : 3832

Key Executives

Name	Title	Year Born
Mr. Hiroshi Nomura	CEO, Pres & Representative Director	1957
Hisayoshi Kashima	Sr. Director & Corp. Controller	NA
Mr. Naoki Noguchi	Exec. Officer of Corp. Governance, Corp. Communications & Sr. Director of Corp. Governance	NA
Mr. Takuya Taguchi	Sr. Exec. Officer & Exe. Director - Sales & Mktg Div. and Deputy Head of Japan Bus. Unit	NA
Ms. Atsuko Higuchi	Sr.. Exec. Officer of External Affairs, Corp. Secretariat & HR	NA
Mr. Yoshiharu Ikeda Ph.D.	Sr. Exe. Officer of Cancer, Modality & Drug Research Div., Head of Japan Busi Unit and Director	1958
Mr. Hiroyuki Baba	Sr. Exe Off. of Global Data Design, Legal Affairs. IP, IT Mgt, & Frontier Bus. Off. and Director	1959
Mr. Toru Kimura Ph.D.	EVP of Global Corp. Strategy, Regenerative & Cellular Medicine Off. and Representative Director	1960
Dr. Shigeyuki Nishinaka Ph.D.	Sr. Exe. Officer of Global Bus. Dev. & International Bus. Management and Director	1964
Mr. Hideyuki Harada	Sr. Exec. Officer of Tech. Research & Dev. Div., Mfg. Div., Deputy Head of Japan Bus. Unit	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.